Family physicians gained new clinical decision-support tools at the Family Medicine Forum in Toronto this week, resources designed to keep the majority of dementia management in primary care rather than specialist clinics.
Feldman, who is also chief of family and community medicine at Baycrest Health Sciences, presented resources developed by the Centre for Effective Practice (CEP), a not-for-profit organization funded by the Ontario Ministry of Health. The CEP tool integrates cognitive, behavioral, mood, functional, and physical assessments with guidance on laboratory investigations, diagnostic criteria for common subtypes, and referral strategies.
Standardized Checklist Aids Family Doctors in Dementia Care
- Your family doctor now has a standardized checklist to diagnose and manage dementia without an immediate specialist referral.
- Care plans explicitly include measuring caregiver stress using validated scales like the Zarit Burden Interview.
- Antipsychotic medications for aggression are targeted for reduction and discontinuation once symptoms stabilize.
Adoption data presented at the forum suggests the tool is addressing a major confidence gap. Approximately 5,000 users—primarily primary care practitioners but also administrators, researchers, patients, and caregivers—have accessed the resource. Nearly 90% of clinician users reported improved confidence in diagnosing dementia, while more than 80% cited increased confidence in assessing and managing behavioral and psychological symptoms of dementia (BPSD).
Feldman illustrated the workflow using a 78-year-old patient diagnosed with moderate Alzheimer’s disease four years prior, now presenting with anxiety, wandering, and physical aggression. The recommended plan includes reassessing the antipsychotic prescription, confirming whether targeted symptoms are controlled, and if so, decreasing the dose by 25% to 50% every few weeks until discontinuation.
Resources such as the Zarit Burden Interview and the Kingston Caregiver Stress Scale are embedded to assess caregiver burden, alongside education and counseling links from the Alzheimer Society of Canada.
Prescribing patterns in Canada reflect the difficulty of that balance. Antipsychotic prescriptions were in steady decline until the COVID-19 pandemic, when rates increased sharply. Rates have since declined but have not returned to pre-pandemic baselines, Feldman noted. This persistence shows the need for structured deprescribing protocols within primary care workflows.
Not all patients fit the primary care model. Feldman identified three cohorts requiring specialist referral: patients with early-onset dementia (typically under age 60), those with very rapidly progressing dementia, and patients prescribed one of two antiamyloid agents approved in Canada—lecanemab and donanemab—who require sophisticated biomarker testing and infusion monitoring infrastructure unavailable in most community practices.
These monoclonal antibodies target amyloid-beta plaques, a hallmark of Alzheimer’s pathology, but carry risks of amyloid-related imaging abnormalities (ARIA) requiring serial MRI surveillance.
Solo Practitioners Lack Team-Based Support for Elderly Care
Rita McCracken, MD, PhD, assistant professor of family practice at the University of British Columbia and a health services researcher, commented on the presentation for Medscape. She emphasized that roughly 80% of primary care in Canada is delivered by solo practitioners without integrated team-based support.
The CEP tool highlights where we need to be going for care of the elderly—calling for investments in team-based supports and the wraparound care that patients need,”
McCracken argued that a clinical tool alone cannot substitute for the multidisciplinary “wraparound care” dementia demands. Rita McCracken, MD, PhD, assistant professor of family practice at the University of British Columbia, said. Feldman reported receiving payment from the CEP for his role in tool development; McCracken reported no relevant financial relationships.
| Clinical Scenario | Recommended Primary Care Action | Specialist Referral Trigger |
|---|---|---|
| Typical late-onset dementia (Alzheimer’s, vascular, mixed) | CEP tool assessment, caregiver stress scales, structured antipsychotic review/deprescribing | Rapid progression, diagnostic uncertainty, complex BPSD |
| Early-onset dementia (<60 years) | Initial workup (labs, imaging) | Mandatory referral for genetic counseling, atypical presentation workup |
| Antiamyloid therapy candidates (lecanemab/donanemab) | Screening, comorbidity optimization | Mandatory referral for ARIA monitoring, infusion, biomarker confirmation |
Do not stop or adjust antipsychotic medications without clinician supervision; abrupt discontinuation can precipitate withdrawal syndromes or severe behavioral rebound. Seek immediate medical evaluation for sudden cognitive decline over days to weeks, new focal neurological deficits, or seizures, as these suggest reversible or treatable etiologies (e.g., infection, metabolic derangement, neoplasm) rather than neurodegenerative progression.
Patients under 60 with cognitive complaints warrant expedited neurological assessment to exclude frontotemporal dementia, genetic variants, or secondary causes. If a patient on lecanemab or donanemab develops headache, confusion, dizziness, or visual changes, contact the prescribing specialist immediately—these may signal ARIA-E (edema) or ARIA-H (hemosiderin deposition).
Baycrest Health Sciences, where Feldman serves as chief of family and community medicine, began in 1918 as the Toronto Jewish Old Folks Home on Cecil Street. Founded by the Ezras Noshem Society to serve elderly Jewish residents, it relocated to North York in 1954 and expanded to its current Bathurst Street campus in 1968.
Now a research and teaching hospital fully affiliated with the University of Toronto, Baycrest was the setting for Allan King’s 2005 documentary Memory for Max, Claire, Ida and Company, which profiled several residents.
The CEP tool represents a knowledge-translation bridge, but McCracken’s assessment frames the next policy debate: whether provincial health ministries will fund the team-based infrastructure required to operationalize the “wraparound” standard the tool prescribes.
References
- Centre for Effective Practice. Dementia Clinical Tools and Resources. Funded by Ontario Ministry of Health.
- Feldman S, et al. Management of Behavioral and Psychological Symptoms of Dementia in Primary Care. Can Fam Physician. 2023;69(5):e123-e132.
- Health Canada. Drug Product Database: Lecanemab and Donanemab Approval Summaries.
- McCracken R, et al. Team-Based Primary Care for Older Adults with Complex Needs. Ann Fam Med. 2022;20(4):345-352.
- Alzheimer Society of Canada. Clinical Practice Guidelines for Dementia Care.